Highly Potent 17β-HSD2 Inhibitors with a Promising Pharmacokinetic Profile for Targeted Osteoporosis Therapy.
Siebenbuerger L, Hernandez-Olmos V, Abdelsamie AS, Frotscher M, van Koppen CJ, Marchais-Oberwinkler S, Scheuer C, Laschke MW, Menger MD, Boerger C, Hartmann RW.
Siebenbuerger L, et al. Among authors: abdelsamie as.
J Med Chem. 2018 Dec 13;61(23):10724-10738. doi: 10.1021/acs.jmedchem.8b01373. Epub 2018 Nov 27.
J Med Chem. 2018.
PMID: 30480443